Zephyr Valve Japan Post-Marketing Surveillance - Trial NCT06332885
Access comprehensive clinical trial information for NCT06332885 through Pure Global AI's free database. This phase not specified trial is sponsored by Pulmonx Corporation and is currently Recruiting. The study focuses on Emphysema,COPD,Severe Emphysema. Target enrollment is 140 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pulmonx Corporation
Timeline & Enrollment
N/A
Mar 12, 2024
Mar 31, 2028
Primary Outcome
Incidence rate of pneumothorax at 45-days post-Zephyr Valve index procedure.
Summary
This is a multicenter, prospective, observational surveillance enrolling 140 consecutive
 patients with severe emphysema who are candidates for bronchoscopic lung volume reduction
 using Zephyr Endobronchial Valve at up to 20 centers across Japan and followed for 12 months.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06332885
Device Trial